On November 25, 2020 Amgen (NASDAQ:AMGN) reported that it will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference (Press release, Amgen, NOV 25, 2020, https://www.prnewswire.com/news-releases/amgen-to-present-at-the-evercore-isi-virtual-healthconx-conference-301180785.html [SID1234571755]). Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 25, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in two upcoming virtual investor conferences (Press release, Arvinas, NOV 25, 2020, View Source [SID1234571717]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020. A pre-recorded fireside chat held with John Houston, Ph.D., President and Chief Executive Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, is available here and on the Events + Presentations section of the Company’s website.

3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020. Ian Taylor, Ph.D., Chief Scientific Officer, and Randy Teel, Ph.D., Vice President of Corporate Development, will participate in a fireside chat at 8:50 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

On November 25, 2020 IsoPlexis, the leader in single-cell functional proteomics, reported that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Evercore ISI’s 3rd Annual HealthCONx Conference on Wednesday, December 2nd at 9:40 a.m. ET (Press release, IsoPlexis, NOV 25, 2020, https://www.prnewswire.com/news-releases/isoplexis-to-present-at-evercore-isis-3rd-annual-healthconx-conference-on-december-2-2020-301180662.html [SID1234571756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be made available on the company’s website at isoplexis.com.

On November 24, 2020 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET (Press release, CRISPR Therapeutics, NOV 24, 2020, View Source [SID1234571647]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

On November 24, 2020 Gilead Sciences, Inc. (Nasdaq: GILD) reported that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 11:20 a.m. Eastern Time (Press release, Gilead Sciences, NOV 24, 2020, http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-present-3rd-annual-evercore-isi-healthconx [SID1234571669]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast can be accessed at the company’s investors page at investors.gilead.com. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.